[go: up one dir, main page]

BRPI1010571A2 - processo para a preparação de um composto útil como um inibidor de tafla. - Google Patents

processo para a preparação de um composto útil como um inibidor de tafla.

Info

Publication number
BRPI1010571A2
BRPI1010571A2 BRPI1010571A BRPI1010571A BRPI1010571A2 BR PI1010571 A2 BRPI1010571 A2 BR PI1010571A2 BR PI1010571 A BRPI1010571 A BR PI1010571A BR PI1010571 A BRPI1010571 A BR PI1010571A BR PI1010571 A2 BRPI1010571 A2 BR PI1010571A2
Authority
BR
Brazil
Prior art keywords
taffla
inhibitor
preparation
compound useful
useful
Prior art date
Application number
BRPI1010571A
Other languages
English (en)
Inventor
Bigot Antony
Wehlan Hermut
Rossen Kai
Kraft Volker
Crocq-Stuerga Véronique
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI1010571A2 publication Critical patent/BRPI1010571A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
BRPI1010571A 2009-05-15 2010-05-11 processo para a preparação de um composto útil como um inibidor de tafla. BRPI1010571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290366 2009-05-15
PCT/EP2010/056426 WO2010130718A1 (en) 2009-05-15 2010-05-11 Process for the preparation of a compound useful as an inhibitor of tafia

Publications (1)

Publication Number Publication Date
BRPI1010571A2 true BRPI1010571A2 (pt) 2019-09-24

Family

ID=41259362

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010571A BRPI1010571A2 (pt) 2009-05-15 2010-05-11 processo para a preparação de um composto útil como um inibidor de tafla.

Country Status (22)

Country Link
US (1) US8865906B2 (pt)
EP (1) EP2430002B1 (pt)
JP (1) JP5706397B2 (pt)
KR (1) KR20120016651A (pt)
CN (1) CN102459192B (pt)
AU (1) AU2010247431B2 (pt)
BR (1) BRPI1010571A2 (pt)
CA (1) CA2760748A1 (pt)
CY (1) CY1114493T1 (pt)
DK (1) DK2430002T3 (pt)
ES (1) ES2431068T3 (pt)
HR (1) HRP20130881T1 (pt)
IL (1) IL216202A (pt)
MX (1) MX2011011849A (pt)
MY (1) MY157304A (pt)
PL (1) PL2430002T3 (pt)
PT (1) PT2430002E (pt)
RS (1) RS52963B (pt)
RU (1) RU2538506C2 (pt)
SG (1) SG176558A1 (pt)
SI (1) SI2430002T1 (pt)
WO (1) WO2010130718A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130006620A (ko) * 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
KR101704095B1 (ko) * 2010-03-18 2017-02-09 다이이찌 산쿄 가부시키가이샤 시클로알킬기로 치환된 이미다졸 유도체
RU2013126689A (ru) 2010-11-11 2014-12-20 Санофи Способ получения производных 3-(6-аминопиридин-3-ил)-2-акриловой кислоты
WO2013076179A1 (en) 2011-11-25 2013-05-30 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9145385B2 (en) 2011-11-25 2015-09-29 Sanofi Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
MX391048B (es) * 2017-03-01 2025-03-21 Boehringer Ingelheim Int Protodescarboxilación catalizada por metales de transición de derivados de ácido a-halo-acrílico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216218A (en) * 1979-02-23 1980-08-05 American Hoechst Corporation Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
IT1177017B (it) * 1984-10-22 1987-08-26 Ravizza Spa Processo per la preparazione dell'acido 2(4-flurofenil)alfa-metil-5-benzox azoloacetico
CN1170822C (zh) * 1998-12-24 2004-10-13 藤泽药品工业株式会社 咪唑化合物及其药物用途
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
US8710232B2 (en) 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors

Also Published As

Publication number Publication date
CA2760748A1 (en) 2010-11-18
RU2011151044A (ru) 2013-06-20
US8865906B2 (en) 2014-10-21
KR20120016651A (ko) 2012-02-24
CN102459192B (zh) 2015-06-24
MY157304A (en) 2016-05-31
IL216202A (en) 2015-07-30
JP5706397B2 (ja) 2015-04-22
US20120245358A1 (en) 2012-09-27
IL216202A0 (en) 2012-01-31
RU2538506C2 (ru) 2015-01-10
EP2430002A1 (en) 2012-03-21
AU2010247431B2 (en) 2015-02-19
JP2012526763A (ja) 2012-11-01
SI2430002T1 (sl) 2013-10-30
CN102459192A (zh) 2012-05-16
WO2010130718A1 (en) 2010-11-18
DK2430002T3 (da) 2013-11-04
MX2011011849A (es) 2011-12-08
PT2430002E (pt) 2013-09-11
SG176558A1 (en) 2012-01-30
RS52963B (en) 2014-02-28
EP2430002B1 (en) 2013-07-24
HK1168102A1 (en) 2012-12-21
ES2431068T3 (es) 2013-11-25
HRP20130881T1 (hr) 2013-10-25
AU2010247431A1 (en) 2011-12-01
CY1114493T1 (el) 2016-10-05
PL2430002T3 (pl) 2013-12-31

Similar Documents

Publication Publication Date Title
BRPI0920356A2 (pt) Processo para a preparação de compostos úteis como inibidores de sglt
BRPI0911254A2 (pt) processo para a preparação de um composto
BRPI0816258A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt
BR112012014490A2 (pt) processo para a preparação substituída de 1-o-acil-2-desóxi-2-fluoro-4-tio-beta-d-arabinofuranoses
BRPI0910916A2 (pt) Processo para a produção de um dianidroaçúcar
BRPI1013561A8 (pt) processo para a preparação de alogliptina
BRPI0916609A2 (pt) Processo para a preparação de um macrociclo
BRPI1012370A2 (pt) processo para a produção de olefinas
BR112014008196A2 (pt) processo para a preparação de um composto
BRPI1012018A2 (pt) processo para preparar um composto
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BRPI1014812A2 (pt) Processo para a produção de alacoóis
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.
BRPI0911897A2 (pt) Processo para a preparação de compostos, e, composto
BR112015003101A2 (pt) processo para a preparação de um composto.
BR112013008883A2 (pt) processo para a fabricação de di-hidropteridinonas
BRPI1013830A2 (pt) Processo para a iodação de compostos aromáticos
BRPI0921882A2 (pt) processo para fabricar um composto.
BRPI0909393A2 (pt) processo para a preparação de polibutadieno
BR112014015512A8 (pt) processo para a preparação de um composto
BR112012009789A2 (pt) processo para a produção de um álcool
BRPI1010571A2 (pt) processo para a preparação de um composto útil como um inibidor de tafla.
BRPI1008117A2 (pt) Processo para a sintese de cleistantina
BR112012001731A2 (pt) Processo para a preparação de 1-benzil-3-hidroximetil-1h-indazol
BRPI1008308A2 (pt) processo para produzir um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.